▲ +302.44% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for DURECT in the last 3 months. The average price target is $6.60, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 302.44% upside from the last price of $1.64.
The current consensus among 6 investment analysts is to buy stock in DURECT. This Buy consensus rating has held steady for over two years.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.